Incidentally Detected Gastrointestinal Stromal Tumor in a Patient with Carcinoma Prostate: 68: Ga-Prostate-Specific Membrane Antigen Versus: 18: F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography : Indian Journal of Nuclear Medicine

Secondary Logo

Journal Logo

Interesting Image

Incidentally Detected Gastrointestinal Stromal Tumor in a Patient with Carcinoma Prostate

68Ga-Prostate-Specific Membrane Antigen Versus 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

Jaleel, Jasim; Subudhi, Tumulu Kishan; Sagar, Sambit; Yadav, Rajni1; Tripathi, Madhavi; Bal, Chandrasekhar

Author Information
Indian Journal of Nuclear Medicine 38(1):p 67-68, Jan–Mar 2023. | DOI: 10.4103/ijnm.ijnm_105_22
  • Open

Abstract

Uptake of 68Ga-prostate-specific membrane antigen (PSMA) in various nonprostatic tumors is well documented in the literature. We present a case of a gastrointestinal stromal tumor, incidentally detected on 68Ga-PSMA positron emission tomography/computed tomography imaging in a patient who underwent imaging for a suspected recurrence of carcinoma prostate.

A 67-year-old male, postrobotic-assisted radical prostatectomy for carcinoma prostate, was referred to our department for 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in view of slowly rising prostate-specific antigen (0.024 ng/ml–0.138 ng/ml). 68Ga-PSMA PET/CT showed a large heterogeneous density mass with increased PSMA uptake in the left subhepatic region, adjacent to the lesser curvature of the stomach [Figure 1]. Contrast-enhanced CT (CECT) showed heterogeneous enhancement of this mass. 18F-fluorodeoxyglucose (FDG) PET/CT showed no significant FDG uptake in the mass [Figure 1]. Ultrasound (USG)-guided biopsy was performed, which was suggestive of gastrointestinal stromal tumor (GIST) [Figure 2].

F1-14
Figure 1:
MIP image of 68Ga-PSMA PET/CT (a) shows increased tracer uptake in the left subhepatic region (white arrow). Axial fused 68Ga-PSMA PET/CT and corresponding NCCT images (b and c) show a large PSMA avid soft tissue density mass (white arrows) in the left subhepatic region. The mass is closely abutting the lesser curvature of the stomach and left lobe of the liver. Axial fused 18F-FDG PET/CT and corresponding CECT images (d and e) show a heterogeneously enhancing soft-tissue density mass (white arrows) with a peripheral necrotic component in the left subhepatic region with no significant FDG uptake. No abnormal FDG uptake was noted in the 18F-FDG PET/CT MIP image (f). MIP: Maximum intensity projection, PET/CT: Positron emission tomography/computed tomography, CECT: Contrast-enhanced CT, FDG: Fluorodeoxyglucose
F2-14
Figure 2:
USG-guided biopsy showing tumor cells arranged in loose ill-defined fascicles and sheets with interspersed blood vessels, H and E ×100 (a) and ×200 (b). The tumor cells are spindled and epithelioid shaped containing oval and round nuclei, respectively, with finely granular nuclear chromatin, inconspicuous nucleoli, and moderate eosinophilic cytoplasm, H and E ×400 (c). The tumor cells demonstrated immunopositivity for DOG1, ×400 (d). Overall findings were suggestive of GIST. GIST: Gastrointestinal stromal tumor

GIST is the most common mesenchymal tumor of the digestive tract. It originates from the interstitial cells of Cajal and is characterized by overexpression of the tyrosine kinase receptor KIT with 95% staining positive for CD117 (c-KIT) and 70% for CD34.[1] GISTs are now considered to be potentially malignant and all nonmetastatic GISTs should be resected.[2] Small GISTs are usually asymptomatic and are usually incidentally detected either during investigations or surgical procedures for unrelated diseases.[3]

GISTs usually appear as rounded soft-tissue masses, arising from the wall of a hollow viscus (most commonly the stomach) with an endoluminal or exophytic growth pattern. It may have a central necrotic zone with peripheral enhancement on CECT. Although GISTs are usually FDG avid,[4] few cases of GISTs with low FDG uptake have been reported.[5] In these cases, FDG PET/CT cannot be used for monitoring response to therapy.[6] Few cases of GIST, incidentally detected on 68Ga-PSMA PET/CT imaging have been reported in the literature.[7,8,9] However, heterogeneity of PSMA and FDG uptake in gastric GIST have never been reported before. In such cases of GISTs which are FDG negative and PSMA positive, 68Ga-PSMA PET/CT should be preferred over 18F-FDG PET/CT for response assessment.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published and due efforts will be made to conceal his identity, but anonymity cannot be guaranteed.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initial s will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Bucher P, Villiger P, Egger JF, Buhler LH, Morel P. Management of gastrointestinal stromal tumors: From diagnosis to treatment Swiss Med Wkly. 2004;134:145–53
2. Akahoshi K, Oya M. Gastrointestinal stromal tumor of the stomach: How to manage? World J Gastrointest Endosc. 2010;2:271–7
3. Ludwig DJ, Traverso LW. Gut stromal tumors and their clinical behavior Am J Surg. 1997;173:390–4
4. Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, et al 18F-fluorodeoxyglucose positron emission tomography: Useful technique for predicting malignant potential of gastrointestinal stromal tumors World J Surg. 2005;29:1429–35
5. Williams A, Gutzeit A, Germer M, Pless M. PET-negative gastrointestinal stromal tumors Case Rep Oncol. 2013;6:508–13
6. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, et al CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings AJR Am J Roentgenol. 2004;183:1619–28
7. Vaz S, Oliveira C, Castanheira JC, Silva ÂF, Costa DC. Gastric GIST incidentally detected on 68Ga-PSMA-PET/CT: Correlation between functional imaging and histology Clin Nucl Med. 2018;43:e488–91
8. Sasikumar A, Joy A, Pillai M, Bindu S, Sudin S. 68Ga-PSMA uptake in an incidentally detected gastrointestinal stromal tumor in a case of suspected carcinoma prostate Clin Nucl Med. 2017;42:e447–8
9. Lee DJW, Warner M, Shannon T, Moschilla J. Incidental finding of ileal gastrointestinal stromal tumour during prostate cancer staging with prostate-specific membrane antigen scan J Med Imaging Radiat Oncol. 2021;65:89–91
Keywords:

Fluorodeoxyglucose; gastrointestinal stromal tumor; positron emission tomography/computed tomography; prostate-specific membrane antigen

© 2023 Indian Journal of Nuclear Medicine | Published by Wolters Kluwer – Medknow